Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Åsa V Keita

Showing results (1-10 of 58) with videos related to

Pageof 6
Sort By:
Cells|March 1, 2019
Cellular and Molecular Therapeutic Targets in Inflammatory Bowel Disease-Focusing on Intestinal Barrier FunctionIda Schoultz, Åsa V Keita
Cells|August 23, 2020
The Intestinal Barrier and Current Techniques for the Assessment of Gut PermeabilityIda Schoultz, Åsa V Keita
Therapeutic Advances in Gastroenterology|April 22, 2020
Potential neuro-immune therapeutic targets in irritable bowel syndromeMaite Casado-Bedmar, Åsa V Keita
Current Opinion in Pharmacology|September 15, 2018
Mucosal permeability and mast cells as targets for functional gastrointestinal disordersÅsa V Keita, Johan D Söderholm
Frontiers in Nutrition|December 26, 2022
A postbiotic fermented oat gruel may have a beneficial effect on the colonic mucosal barrier in patients with irritable bowel syndromeOlga Bednarska, Olga Biskou, Hans Israelsen, et al.
Frontiers in Medicine|July 19, 2024
ReFerm<sup>®</sup>: a postbiotic fermented oat gruel composition is reducing mast cell degranulation in the colon of patients with irritable bowel syndromeOlga Biskou, Susanna Walter, Hans Israelsen, et al.
Cells|July 7, 2019
Possible Involvement of Intracellular Calcium-Independent Phospholipase A<sub>2</sub> in the Release of Secretory Phospholipases from Mast Cells-Increased Expression in Ileal Mast Cells of Crohn's DiseaseUlrika Christerson, Åsa V Keita, Martin E Winberg, et al.
Neurogastroenterology and Motility|November 9, 2018
Upregulation of intestinal mucosal mast cells expressing VPAC1 in close proximity to vasoactive intestinal polypeptide in inflammatory bowel disease and murine colitisMaite Casado-Bedmar, Stéphanie D S Heil, Pär Myrelid, et al.
Journal of Crohn'S & Colitis|April 17, 2018
Gut Barrier Dysfunction-A Primary Defect in Twins with Crohn's Disease Predominantly Caused by Genetic PredispositionÅsa V Keita, Carl Mårten Lindqvist, Åke Öst, et al.
Neurogastroenterology and Motility|June 24, 2026
ReFerm® a Fermented Oat Gruel Composition, Improves Colonic Barrier Function and Modulates Tricellulin Expression in Patients With Irritable Bowel SyndromeVittorio Abruzzese, Olga Biskou, Martin E Winberg, et al.
Pageof 6

Showing results (1-10 of 58) with videos related to

Sort By:
Pageof 6
Cells|March 1, 2019
Cellular and Molecular Therapeutic Targets in Inflammatory Bowel Disease-Focusing on Intestinal Barrier FunctionIda Schoultz, Åsa V Keita
Cells|August 23, 2020
The Intestinal Barrier and Current Techniques for the Assessment of Gut PermeabilityIda Schoultz, Åsa V Keita
Therapeutic Advances in Gastroenterology|April 22, 2020
Potential neuro-immune therapeutic targets in irritable bowel syndromeMaite Casado-Bedmar, Åsa V Keita
Current Opinion in Pharmacology|September 15, 2018
Mucosal permeability and mast cells as targets for functional gastrointestinal disordersÅsa V Keita, Johan D Söderholm
Frontiers in Nutrition|December 26, 2022
A postbiotic fermented oat gruel may have a beneficial effect on the colonic mucosal barrier in patients with irritable bowel syndromeOlga Bednarska, Olga Biskou, Hans Israelsen, et al.
Frontiers in Medicine|July 19, 2024
ReFerm<sup>®</sup>: a postbiotic fermented oat gruel composition is reducing mast cell degranulation in the colon of patients with irritable bowel syndromeOlga Biskou, Susanna Walter, Hans Israelsen, et al.
Cells|July 7, 2019
Possible Involvement of Intracellular Calcium-Independent Phospholipase A<sub>2</sub> in the Release of Secretory Phospholipases from Mast Cells-Increased Expression in Ileal Mast Cells of Crohn's DiseaseUlrika Christerson, Åsa V Keita, Martin E Winberg, et al.
Neurogastroenterology and Motility|November 9, 2018
Upregulation of intestinal mucosal mast cells expressing VPAC1 in close proximity to vasoactive intestinal polypeptide in inflammatory bowel disease and murine colitisMaite Casado-Bedmar, Stéphanie D S Heil, Pär Myrelid, et al.
Journal of Crohn'S & Colitis|April 17, 2018
Gut Barrier Dysfunction-A Primary Defect in Twins with Crohn's Disease Predominantly Caused by Genetic PredispositionÅsa V Keita, Carl Mårten Lindqvist, Åke Öst, et al.
Neurogastroenterology and Motility|June 24, 2026
ReFerm® a Fermented Oat Gruel Composition, Improves Colonic Barrier Function and Modulates Tricellulin Expression in Patients With Irritable Bowel SyndromeVittorio Abruzzese, Olga Biskou, Martin E Winberg, et al.
Pageof 6